Multi-angle effector function analysis of human monoclonal IgG Glycovariants

PLoS ONE

Volumn 10, Issue 12, 2015, Pages

  Dashivets, Tetyana ^a,c   Thomann, Marco ^b   Rueger, Petra ^a   Knaupp, Alexander ^a   Buchner, Johannes ^c   Schlothauer, Tilman ^a  

^a ROCHE INNOVATION CENTER MUNICH   (Germany)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FC GAMMA RECEPTOR I; FC GAMMA RECEPTOR II; FC GAMMA RECEPTOR IIIA; FC RECEPTOR; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G1 G0 GLYCOVARIANT; IMMUNOGLOBULIN G1 G1 + 1SA GLYCOVARIANT; IMMUNOGLOBULIN G1 G1 GLYCOVARIANT; IMMUNOGLOBULIN G1 G2 + 1SA GLYCOVARIANT; IMMUNOGLOBULIN G1 G2 + 2SA GLYCOVARIANT; IMMUNOGLOBULIN G1 G2 GLYCOVARIANT; IMMUNOGLOBULIN G1 M3 GLYCOVARIANT; UNCLASSIFIED DRUG; ANTIGEN ANTIBODY COMPLEX; FC RECEPTOR IIA; FCGR1A PROTEIN, HUMAN; GALACTOSE; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; PROTEIN BINDING; RECOMBINANT PROTEIN; SIALIC ACID DERIVATIVE;

ANTIBODY STRUCTURE; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; BINDING AFFINITY; CELL SURFACE; ENZYME GLYCOSYLATION; HUMAN; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN STRUCTURE; STRUCTURE ANALYSIS; SURFACE PLASMON RESONANCE; WILD TYPE; AFFINITY CHROMATOGRAPHY; ANTIBODY AFFINITY; CARBOHYDRATE ANALYSIS; CELL LINE; CHEMISTRY; GENE EXPRESSION; GENETICS; GLYCOSYLATION; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; PROTEIN ENGINEERING;

ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTIGEN-ANTIBODY COMPLEX; CARBOHYDRATE SEQUENCE; CELL LINE; CHROMATOGRAPHY, AFFINITY; GALACTOSE; GENE EXPRESSION; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTEIN ENGINEERING; PROTEIN STABILITY; RECEPTORS, IGG; RECOMBINANT PROTEINS; SIALIC ACIDS; SURFACE PLASMON RESONANCE;

EID: 84952366430     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0143520     Document Type: Article

References (95)

1. Brorson K, Jia AY. Therapeutic monoclonal antibodies and consistent ends: Terminal heterogeneity, detection, and impact on quality. Curr Opin Biotechnol 2014 Jul 11; 30C:140-6.
2. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012 Apr; 12(4):278-87. doi: 10.1038/nrc3236 PMID: 22437872
3. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 2009 Mar; 8(3):226-34. doi: 10.1038/nrd2804 PMID: 19247305
4. Gessner JE, Heiken H, Tamm A, Schmidt RE. The IgG Fc receptor family. Ann Hematol 1998 Jun; 76 (6):231-48. PMID: 9692811
5. Hogarth PM, Hulett MD, Osman N. Fc gamma receptors: Gene structure and receptor function. Immunol Res 1992; 11(3-4):217-25. PMID: 1287117
6. Hogarth PM, Pietersz GA. Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat Rev Drug Discov 2012 Apr; 11(4):311-31. doi: 10.1038/nrd2909 PMID: 22460124
7. Jefferis R, Lund J. Interaction sites on human IgG-Fc for FcgammaR: Current models. Immunol Lett 2002 Jun 3; 82(1-2):57-65. PMID: 12008035
8. Jiang XR, Song A, Bergelson S, Arroll T, Parekh B, May K, et al. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov 2011 Feb; 10(2):101-11. doi: 10.1038/nrd3365 PMID: 21283105
9. Kapur R, Einarsdottir HK, Vidarsson G. IgG-effector functions: "The Good, The Bad and The Ugly". Immunol Lett 2014 Feb 1.
10. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 2009 Apr 16; 113(16):3716-25. doi: 10.1182/blood-2008-09-179754 PMID: 19018092
11. Baker K, Qiao SW, Kuo TT, Aveson VG, Platzer B, Andersen JT, et al. Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8-CD11b+ dendritic cells. Proc Natl Acad Sci U S A 2011 Jun 14; 108(24):9927-32. doi: 10.1073/pnas.1019037108 PMID: 21628593
12. Baker K, Rath T, Pyzik M, Blumberg RS. The Role of FcRn in Antigen Presentation. Front Immunol 2014; 5:408. doi: 10.3389/fimmu.2014.00408 PMID: 25221553
13. Rath T, Kuo TT, Baker K, Qiao SW, Kobayashi K, Yoshida M, et al. The immunologic functions of the neonatal Fc receptor for IgG. J Clin Immunol 2013 Jan; 33 Suppl 1:S9-17. doi: 10.1007/s10875-012-9768-y PMID: 22948741
14. Roopenian DC, Akilesh S. FcRn: The neonatal Fc receptor comes of age. Nat Rev Immunol 2007 Sep; 7(9):715-25. PMID: 17703228
15. Anthony RM, Wermeling F, Ravetch JV. Novel roles for the IgG Fc glycan. Ann N Y Acad Sci 2012 Apr; 1253:170-80. doi: 10.1111/j.1749-6632.2011.06305.x PMID: 22288459
16. Arnold JN, Dwek RA, Rudd PM, Sim RB. Mannan binding lectin and its interaction with immunoglobulins in health and in disease. Immunol Lett 2006 Aug 15; 106(2):103-10. PMID: 16814399
17. Jefferis R. The glycosylation of antibody molecules: Functional significance. Glycoconj J 1993 Oct; 10 (5):358-61. PMID: 8298303
18. Kapur R, Einarsdottir HK, Vidarsson G. IgG-effector functions: "The Good, The Bad and The Ugly". Immunol Lett 2014 Feb 1.
19. Nimmerjahn F, Ravetch JV. Fc-receptors as regulators of immunity. Adv Immunol 2007; 96:179-204. PMID: 17981207
20. Xue J, Zhu LP, Wei Q. IgG-Fc N-glycosylation at Asn297 and IgA O-glycosylation in the hinge region in health and disease. Glycoconj J 2013 Nov; 30(8):735-45. doi: 10.1007/s10719-013-9481-y PMID: 23783413
21. Anthony RM, Wermeling F, Ravetch JV. Novel roles for the IgG Fc glycan. Ann N Y Acad Sci 2012 Apr; 1253:170-80. doi: 10.1111/j.1749-6632.2011.06305.x PMID: 22288459
22. Hogarth PM, Pietersz GA. Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat Rev Drug Discov 2012 Apr; 11(4):311-31. doi: 10.1038/nrd2909 PMID: 22460124
23. Jiang XR, Song A, Bergelson S, Arroll T, Parekh B, May K, et al. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov 2011 Feb; 10(2):101-11. doi: 10.1038/nrd3365 PMID: 21283105
24. Ferrara C, Stuart F, Sondermann P, Brunker P, Umana P. The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J Biol Chem 2006 Feb 24; 281(8):5032-6. PMID: 16330541
25. Jefferis R, Lund J, Goodall M. Recognition sites on human IgG for Fc gamma receptors: The role of glycosylation. Immunol Lett 1995 Jan; 44(2-3):111-7. PMID: 7797239
26. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 2009 Mar; 8(3):226-34. doi: 10.1038/nrd2804 PMID: 19247305
27. Shibata-Koyama M, Iida S, Misaka H, Mori K, Yano K, Shitara K, et al. Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcgammaRIIIb and MHC class II expression on the phagocytotic neutrophils. Exp Hematol 2009 Mar; 37(3):309-21. doi: 10.1016/j. exphem.2008.11.006 PMID: 19218011
28. Raju TS. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol 2008 Aug; 20(4):471-8. doi: 10.1016/j.coi.2008.06.007 PMID: 18606225
29. Houde D, Peng Y, Berkowitz SA, Engen JR. Post-translational modifications differentially affect IgG1 conformation and receptor binding. Mol Cell Proteomics 2010 Aug; 9(8):1716-28. doi: 10.1074/mcp. M900540-MCP200 PMID: 20103567
30. Kumpel BM, Wang Y, Griffiths HL, Hadley AG, Rook GA. The biological activity of human monoclonal IgG anti-D is reduced by beta-galactosidase treatment. Hum Antibodies Hybridomas 1995; 6(3):82-8. PMID: 8597627
31. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006 Aug 4; 313(5787):670-3. PMID: 16888140
32. Nimmerjahn F, Ravetch JV. Antibody-mediated modulation of immune responses. Immunol Rev 2010 Jul; 236:265-75. doi: 10.1111/j.1600-065X.2010.00910.x PMID: 20636822
33. Bohm S, Schwab I, Lux A, Nimmerjahn F. The role of sialic acid as a modulator of the anti-inflammatory activity of IgG. Semin Immunopathol 2012 May; 34(3):443-53. doi: 10.1007/s00281-012-0308-x PMID: 22437760
34. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006 Aug 4; 313(5787):670-3. PMID: 16888140
35. Boyd PN, Lines AC, Patel AK. The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Mol Immunol 1995 Dec; 32(17-18):1311-8. PMID: 8643100
36. Huang W, Giddens J, Fan SQ, Toonstra C, Wang LX. Chemoenzymatic glycoengineering of intact IgG antibodies for gain of functions. J Am Chem Soc 2012 Jul 25; 134(29):12308-18. doi: 10.1021/ja3051266 PMID: 22747414
37. Jefferis R. Glycosylation of antibody therapeutics: Optimisation for purpose. Methods Mol Biol 2009; 483:223-38. doi: 10.1007/978-1-59745-407-0-13 PMID: 19183902
38. Huang W, Giddens J, Fan SQ, Toonstra C, Wang LX. Chemoenzymatic glycoengineering of intact IgG antibodies for gain of functions. J Am Chem Soc 2012 Jul 25; 134(29):12308-18. doi: 10.1021/ja3051266 PMID: 22747414
39. Jung ST, Kang TH, Kelton W, Georgiou G. Bypassing glycosylation: Engineering aglycosylated fulllength IgG antibodies for human therapy. Curr Opin Biotechnol 2011 Dec; 22(6):858-67. doi: 10.1016/j. copbio.2011.03.002 PMID: 21420850
40. Zhang A, Hu P, Macgregor P, Xue Y, Fan H, Suchecki P, et al. Understanding the conformational impact of chemical modifications on monoclonal antibodies with diverse sequence variation using hydrogen/deuterium exchange mass spectrometry and structural modeling. Anal Chem 2014 Apr 1; 86 (7):3468-75. doi: 10.1021/ac404130a PMID: 24597564
41. Anthony RM, Nimmerjahn F. The role of differential IgG glycosylation in the interaction of antibodies with FcgammaRs in vivo. Curr Opin Organ Transplant 2011 Feb; 16(1):7-14. doi: 10.1097/MOT. 0b013e328342538f PMID: 21150612
42. Raju TS. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol 2008 Aug; 20(4):471-8. doi: 10.1016/j.coi.2008.06.007 PMID: 18606225
43. Lux A, Yu X, Scanlan CN, Nimmerjahn F. Impact of immune complex size and glycosylation on IgG binding to human FcgammaRs. J Immunol 2013 Apr 15; 190(8):4315-23. doi: 10.4049/jimmunol. 1200501 PMID: 23509345
44. Oda M, Kozono H, Morii H, Azuma T. Evidence of allosteric conformational changes in the antibody constant region upon antigen binding. Int Immunol 2003 Mar; 15(3):417-26. PMID: 12618486
45. Sela-Culang I, Alon S, Ofran Y. A systematic comparison of free and bound antibodies reveals bindingrelated conformational changes. J Immunol 2012 Nov 15; 189(10):4890-9. doi: 10.4049/jimmunol. 1201493 PMID: 23066154
46. Thomann M, Schlothauer T, Dashivets T, Malik S, Avenal C, Bulau P, et al. In Vitro Glycoengineering of IgG1 and Its Effect on Fc Receptor Binding and ADCC Activity. PLoS One 2015; 10(8):e0134949. doi: 10.1371/journal.pone.0134949 PMID: 26266936
47. Buck PM, Kumar S, Singh SK. Consequences of glycan truncation on Fc structural integrity. MAbs 2013 Nov; 5(6):904-16. doi: 10.4161/mabs.26453 PMID: 24492344
48. Kayser V, Chennamsetty N, Voynov V, Forrer K, Helk B, Trout BL. Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies. Biotechnol J 2011 Jan; 6(1):38-44. doi: 10.1002/biot.201000091 PMID: 20949542
49. Mimura Y, Church S, Ghirlando R, Ashton PR, Dong S, Goodall M, et al. The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: Properties of a series of truncated glycoforms. Mol Immunol 2000 Aug; 37(12-13):697-706. PMID: 11275255
50. Zheng K, Bantog C, Bayer R. The impact of glycosylation on monoclonal antibody conformation and stability. MAbs 2011 Nov; 3(6):568-76. doi: 10.4161/mabs.3.6.17922 PMID: 22123061
51. Ericsson UB, Hallberg BM, Detitta GT, Dekker N, Nordlund P. Thermofluor-based high-throughput stability optimization of proteins for structural studies. Anal Biochem 2006 Oct 15; 357(2):289-98. PMID: 16962548
52. Pantoliano MW, Petrella EC, Kwasnoski JD, Lobanov VS, Myslik J, Graf E, et al. High-density miniaturized thermal shift assays as a general strategy for drug discovery. J Biomol Screen 2001 Dec; 6 (6):429-40. PMID: 11788061
53. Vermeer AW, Norde W. The thermal stability of immunoglobulin: Unfolding and aggregation of a multidomain protein. Biophys J 2000 Jan; 78(1):394-404. PMID: 10620303
54. Mimura Y, Church S, Ghirlando R, Ashton PR, Dong S, Goodall M, et al. The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: Properties of a series of truncated glycoforms. Mol Immunol 2000 Aug; 37(12-13):697-706. PMID: 11275255
55. Buck PM, Kumar S, Singh SK. Consequences of glycan truncation on Fc structural integrity. MAbs 2013 Nov; 5(6):904-16. doi: 10.4161/mabs.26453 PMID: 24492344
56. Kayser V, Chennamsetty N, Voynov V, Forrer K, Helk B, Trout BL. Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies. Biotechnol J 2011 Jan; 6(1):38-44. doi: 10.1002/biot.201000091 PMID: 20949542
57. Zheng K, Yarmarkovich M, Bantog C, Bayer R, Patapoff TW. Influence of glycosylation pattern on the molecular properties of monoclonal antibodies. MAbs 2014 May; 6(3):649-58. doi: 10.4161/mabs. 28588 PMID: 24662970
58. Zeck A, Pohlentz G, Schlothauer T, Peter-Katalinic J, Regula JT. Cell type-specific and site directed Nglycosylation pattern of FcgammaRIIIa. J Proteome Res 2011 Jul 1; 10(7):3031-9. doi: 10.1021/pr1012653 PMID: 21561106
59. Hayes JM, Frostell A, Cosgrave EF, Struwe WB, Potter O, Davey GP, et al. Fc gamma receptor glycosylation modulates the binding of IgG glycoforms: A requirement for stable antibody interactions. J Proteome Res 2014 Dec 5; 13(12):5471-85. doi: 10.1021/pr500414q PMID: 25345863
60. Bohm S, Schwab I, Lux A, Nimmerjahn F. The role of sialic acid as a modulator of the anti-inflammatory activity of IgG. Semin Immunopathol 2012 May; 34(3):443-53. doi: 10.1007/s00281-012-0308-x PMID: 22437760
61. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006 Aug 4; 313(5787):670-3. PMID: 16888140
62. Scallon BJ, Tam SH, McCarthy SG, Cai AN, Raju TS. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol Immunol 2007 Mar; 44(7):1524-34. PMID: 17045339
63. Schlothauer T, Rueger P, Stracke JO, Hertenberger H, Fingas F, Kling L, et al. Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies. MAbs 2013 Jul; 5(4):576-86. doi: 10.4161/mabs.24981 PMID: 23765230
64. Stracke J, Emrich T, Rueger P, Schlothauer T, Kling L, Knaupp A, et al. A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies. MAbs 2014 Jul 1; 6(5).
65. Ghetie V, Ward ES. Multiple roles for the major histocompatibility complex class I-related receptor FcRn. Annu Rev Immunol 2000; 18:739-66. PMID: 10837074
66. Jefferis R. Isotype and glycoform selection for antibody therapeutics. Arch Biochem Biophys 2012 Oct 15; 526(2):159-66. doi: 10.1016/j.abb.2012.03.021 PMID: 22465822
67. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 2001 Mar 2; 276(9):6591-604. PMID: 11096108
68. Leabman MK, Meng YG, Kelley RF, DeForge LE, Cowan KJ, Iyer S. Effects of altered FcgammaR binding on antibody pharmacokinetics in cynomolgus monkeys. MAbs 2013 Nov; 5(6):896-903. doi: 10. 4161/mabs.26436 PMID: 24492343
69. Anthony RM, Wermeling F, Ravetch JV. Novel roles for the IgG Fc glycan. Ann N Y Acad Sci 2012 Apr; 1253:170-80. doi: 10.1111/j.1749-6632.2011.06305.x PMID: 22288459
70. Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 2007; 25:21-50. PMID: 17029568
71. Hristodorov D, Fischer R, Joerissen H, Muller-Tiemann B, Apeler H, Linden L. Generation and comparative characterization of glycosylated and aglycosylated human IgG1 antibodies. Mol Biotechnol 2013 Mar; 53(3):326-35. doi: 10.1007/s12033-012-9531-x PMID: 22427250
72. Jefferis R. The glycosylation of antibody molecules: Functional significance. Glycoconj J 1993 Oct; 10 (5):358-61. PMID: 8298303
73. Jefferis R. Isotype and glycoform selection for antibody therapeutics. Arch Biochem Biophys 2012 Oct 15; 526(2):159-66. doi: 10.1016/j.abb.2012.03.021 PMID: 22465822
74. Buck PM, Kumar S, Singh SK. Consequences of glycan truncation on Fc structural integrity. MAbs 2013 Nov; 5(6):904-16. doi: 10.4161/mabs.26453 PMID: 24492344
75. Jefferis R. Isotype and glycoform selection for antibody therapeutics. Arch Biochem Biophys 2012 Oct 15; 526(2):159-66. doi: 10.1016/j.abb.2012.03.021 PMID: 22465822
76. Kayser V, Chennamsetty N, Voynov V, Forrer K, Helk B, Trout BL. Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies. Biotechnol J 2011 Jan; 6(1):38-44. doi: 10.1002/biot.201000091 PMID: 20949542
77. Mimura Y, Church S, Ghirlando R, Ashton PR, Dong S, Goodall M, et al. The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: Properties of a series of truncated glycoforms. Mol Immunol 2000 Aug; 37(12-13):697-706. PMID: 11275255
78. Raju TS. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol 2008 Aug; 20(4):471-8. doi: 10.1016/j.coi.2008.06.007 PMID: 18606225
79. Zheng K, Bantog C, Bayer R. The impact of glycosylation on monoclonal antibody conformation and stability. MAbs 2011 Nov; 3(6):568-76. doi: 10.4161/mabs.3.6.17922 PMID: 22123061
80. Houde D, Peng Y, Berkowitz SA, Engen JR. Post-translational modifications differentially affect IgG1 conformation and receptor binding. Mol Cell Proteomics 2010 Aug; 9(8):1716-28. doi: 10.1074/mcp. M900540-MCP200 PMID: 20103567
81. Yamaguchi Y, Nishimura M, Nagano M, Yagi H, Sasakawa H, Uchida K, et al. Glycoform-dependent conformational alteration of the Fc region of human immunoglobulin G1 as revealed by NMR spectroscopy. Biochim Biophys Acta 2006 Apr; 1760(4):693-700. PMID: 16343775
82. Ito K, Furukawa J, Yamada K, Tran NL, Shinohara Y, Izui S. Lack of galactosylation enhances the pathogenic activity of IgG1 but Not IgG2a anti-erythrocyte autoantibodies. J Immunol 2014 Jan 15; 192 (2):581-8. doi: 10.4049/jimmunol.1302488 PMID: 24337750
83. Yamada K, Ito K, Furukawa J, Nakata J, Alvarez M, Verbeek JS, et al. Galactosylation of IgG1 modulates FcgammaRIIB-mediated inhibition of murine autoimmune hemolytic anemia. J Autoimmun 2013 Dec; 47:104-10. doi: 10.1016/j.jaut.2013.09.001 PMID: 24055197
84. Krapp S, Mimura Y, Jefferis R, Huber R, Sondermann P. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol 2003 Jan 31; 325 (5):979-89. PMID: 12527303
85. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006 Aug 4; 313(5787):670-3. PMID: 16888140
86. Anthony RM, Wermeling F, Karlsson MC, Ravetch JV. Identification of a receptor required for the antiinflammatory activity of IVIG. Proc Natl Acad Sci U S A 2008 Dec 16; 105(50):19571-8. doi: 10.1073/pnas.0810163105 PMID: 19036920
87. Park-Min KH, Serbina NV, Yang W, Ma X, Krystal G, Neel BG, et al. FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity 2007 Jan; 26(1):67-78. PMID: 17239631
88. Karsten CM, Pandey MK, Figge J, Kilchenstein R, Taylor PR, Rosas M, et al. Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcgammaRIIB and dectin-1. Nat Med 2012 Sep; 18(9):1401-6. PMID: 22922409
89. Lux A, Yu X, Scanlan CN, Nimmerjahn F. Impact of immune complex size and glycosylation on IgG binding to human FcgammaRs. J Immunol 2013 Apr 15; 190(8):4315-23. doi: 10.4049/jimmunol.1200501 PMID345
90. Nimmerjahn F, Ravetch JV. Analyzing antibody-Fc-receptor interactions. Methods Mol Biol 2008; 415:151-62. doi: 10.1007/978-1-59745-570-1-9 PMID: 18370153
91. Nimmerjahn F, Ravetch JV. FcgammaRs in health and disease. Curr Top Microbiol Immunol 2011; 350:105-25. doi: 10.1007/82-2010-86 PMID: 20680807
92. Roopenian DC, Akilesh S. FcRn: The neonatal Fc receptor comes of age. Nat Rev Immunol 2007 Sep; 7(9):715-25. PMID: 17703228
93. Kanda Y, Yamada T, Mori K, Okazaki A, Inoue M, Kitajima-Miyama K, et al. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: The high-mannose, hybrid, and complex types. Glycobiology 2007 Jan; 17(1):104-18. PMID: 17012310
94. Leabman MK, Meng YG, Kelley RF, DeForge LE, Cowan KJ, Iyer S. Effects of altered FcgammaR binding on antibody pharmacokinetics in cynomolgus monkeys. MAbs 2013 Nov; 5(6):896-903. doi: 10. 4161/mabs.26436 PMID: 24492343
95. Wang W, Lu P, Fang Y, Hamuro L, Pittman T, Carr B, et al. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences. Drug Metab Dispos 2011 Sep; 39(9):1469-77. doi: 10.1124/dmd.111.039453 PMID: 21610128